Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL
December 21st 2023Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.
Oncologists Explore Treatment Options in LGSOC, Look Toward Promising Future
Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Data Reveal Medicaid Expansion May Result in Mortality Rate Reductions for Patients With Cancer
October 24th 2023As a result of the Affordable Care Act’s Medicaid expansion, positive trends are becoming apparent regarding mortality rates for patients with cancer living in the states that have adopted Medicaid expansion.
Dr Zhou on Ongoing Investigations into the Treatment of Patients With Myelofibrosis and Anemia
October 20th 2023Amy W. Zhou, MD, discusses ongoing and planned trials that may enhance therapeutic options for patients with myelofibrosis and anemia that are currently taking place at the Washington University School of Medicine in St. Louis.
Dr Zhou on the Use of Combination Therapies in Myelofibrosis
October 13th 2023Amy W. Zhou, MD, discusses combination therapies with ruxolitinib that may contribute to the treatment paradigm for patients with myelofibrosis, highlighting the importance of continued research with phase 3 confirmatory trials for patients with this disease.
Dr Zhou on the Evaluation of Combination Therapies With Ruxolitinib in Myelofibrosis
September 28th 2023Amy W. Zhou, MD, discusses the investigation of ruxolitinib given in conjunction with novel or emerging agents such as pacritinib and momelotinib, highlighting these agents’ potential at contributing to the treatment paradigm in myelofibrosis.
Ongoing Trials Could Shift BTK Inhibitors to Earlier Settings in MCL
Brad S. Kahl, MD, discusses the evolving role of BTK inhibitors in the treatment of patients with mantle cell lymphoma, expands on key ongoing trials investigating these agents in earlier settings and in different combinations, and expands on what the addition of pirtobrutinib to the treatment arsenal has meant for this population.